A new radioactive version of the element scandium has been produced in Australia's OPAL reactor for the first time. Scandium-47 has the potential for theragnostic use, that is, both as a therapeutic drug and a diagnostic agent, and has similar properties to lutetium-177, which is already being used in clinical trials.
The radioisotope was produced by Australian nuclear science and technology organization ANSTO's biosciences radioisotope development team of Paul Pellegrini, Leena Hogan and Attila Stopic, supported by Mike Izard and Ivan Greguric.
To read more please visit:
https://www.world-nuclear-news.org/Articles/Australia-produces-first-batch-of-medical-isotope
Source: World Nuclear News